RecruitingPhase 2NCT05872204
Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
Studying Malignant non-epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Principal Investigator
- Els Van Nieuwenhuysen, MD PhD, MD, PhDUZ Leuven
- Intervention
- Abemaciclib(drug)
- Enrollment
- 100 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2023 – 2028
Study locations (12)
- CHU de Liège, Liège, Liège, Belgium
- UZ Gent, Ghent, Oost-Vlaanderen, Belgium
- UZ Leuven, Leuven, Vlaams-Brabant, Belgium
- Institut De Cancerologie Strasbourg Europe, Strasbourg, Bas-Rhin, France
- Institut Bergonie, Bordeaux, Gironde, France
- Institut Universitaire Du Cancer Toulouse-Oncopole, Toulouse, Haute-Garonne, France
- Institut De Cancerologie De L'Ouest, Saint-Herblain, Loire-Atlantique, France
- Centre Leon Berard, Lyon, Métropole de Lyon, France
- Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, Île-de-France Region, France
- University Medical Center Groningen, Groningen, Provincie Groningen, Netherlands
- Erasmus Medical Center Rotterdam, Rotterdam, South Holland, Netherlands
- University Medical Center Utrecht, Utrecht, Utrecht, Netherlands
Collaborators
Kom Op Tegen Kanker · Eli Lilly and Company · European Network of Gynaecological Oncological Trial Groups (ENGOT)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05872204 on ClinicalTrials.govOther trials for Malignant non-epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07189871177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsRadiopharm Theranostics, Ltd
- RECRUITINGPHASE1NCT07216105FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsFate Therapeutics
- RECRUITINGPHASE1NCT06238479A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsEli Lilly and Company
- ACTIVE NOT RECRUITINGPHASE2NCT06169124Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT04644289WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOCAGO Research GmbH
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04180371Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionBicycleTx Limited
See all trials for Malignant non-epithelial tumor of ovary →